Literature DB >> 22271315

Developmental incompatibility of human parthenogenetic embryonic stem cells in mouse blastocysts.

Lili Du1, Xiaoming Xu, Xin Duan, Guangxiu Lu, Ge Lin.   

Abstract

Human parthenogenetic embryonic stem (pES) cells can be clinically used in the future to avoid immunological rejection. However, the developmental potential of human pES cells remains to be elucidated. In this study, we generated a human pES-enhanced green fluorescent protein (EGFP) cell line (chHES-32-EGFP), which shows pluripotency thus far and maintains stable and robust EGFP expression in the undifferentiated and differentiated states in vivo and in vitro. Using this pES-EGFP cell line, we found that when human pES-EGFP cells were injected into mice blastocysts, EGFP-positive cells progressively decreased with the development of blastocysts in vitro. Only 4 out of 23 embryos (17.4%) contained EGFP-positive cells and all of these embryos exhibited abnormal morphology or delayed development when the chimera blastocysts were implanted into the pseudopregnant recipient mouse uterus. These results raise serious questions regarding the feasibility of the generation of interspecific chimeras between mouse blastocysts and human pES cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271315     DOI: 10.1007/s11626-012-9483-2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  25 in total

1.  The prophylactic use of antibiotics in cell culture.

Authors:  I Kuhlmann
Journal:  Cytotechnology       Date:  1995-06       Impact factor: 2.058

2.  The hESC line Envy expresses high levels of GFP in all differentiated progeny.

Authors:  Magdaline Costa; Mirella Dottori; Elizabeth Ng; Susan M Hawes; Koula Sourris; Pegah Jamshidi; Martin F Pera; Andrew G Elefanty; Edouard G Stanley
Journal:  Nat Methods       Date:  2005-03-23       Impact factor: 28.547

3.  Derivation of human embryonic stem cell lines from parthenogenetic blastocysts.

Authors:  Qingyun Mai; Yang Yu; Tao Li; Liu Wang; Mei-jue Chen; Shu-zhen Huang; Canquan Zhou; Qi Zhou
Journal:  Cell Res       Date:  2007-12       Impact factor: 25.617

4.  Contribution of human embryonic stem cells to mouse blastocysts.

Authors:  Daylon James; Scott A Noggle; Tomasz Swigut; Ali H Brivanlou
Journal:  Dev Biol       Date:  2006-07-01       Impact factor: 3.582

5.  Integration and differentiation of human embryonic stem cells transplanted to the chick embryo.

Authors:  Ronald S Goldstein; Micha Drukker; Benjamin E Reubinoff; Nissim Benvenisty
Journal:  Dev Dyn       Date:  2002-09       Impact factor: 3.780

6.  Dopaminergic neurons derived from BG01V2, a variant of human embryonic stem cell line BG01.

Authors:  Tandis Vazin; Jia Chen; Charles E Spivak; Rose Amable; Emily Gabitzsch; Chun-Ting Lee; Carl R Lupica; William J Freed
Journal:  Restor Neurol Neurosci       Date:  2008       Impact factor: 2.406

7.  Interspecific chimaerism between sheep and goat.

Authors:  C B Fehilly; S M Willadsen; E M Tucker
Journal:  Nature       Date:  1984 Feb 16-22       Impact factor: 49.962

8.  HLA homozygous stem cell lines derived from human parthenogenetic blastocysts.

Authors:  E S Revazova; N A Turovets; O D Kochetkova; L S Agapova; J L Sebastian; M V Pryzhkova; V I U Smolnikova; L N Kuzmichev; J D Janus
Journal:  Cloning Stem Cells       Date:  2008-03

9.  Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer.

Authors:  Kitai Kim; Kitwa Ng; Peter J Rugg-Gunn; Jae-Hung Shieh; Oktay Kirak; Rudolf Jaenisch; Teruhiko Wakayama; Malcolm A Moore; Roger A Pedersen; George Q Daley
Journal:  Cell Stem Cell       Date:  2007-08-02       Impact factor: 24.633

10.  Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera.

Authors:  M William Lensch; Thorsten M Schlaeger; Leonard I Zon; George Q Daley
Journal:  Cell Stem Cell       Date:  2007-08-23       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.